Personalized cancer care.

The completion of the Human Genome Project in 2003 has led to the development of molecular profiling platforms that have changed the trajectory of cancer care. These technologies continue to advance, and with the development of next-generation sequencing, targeted gene panels are now commercially available to analyze DNA, RNA, and protein biomarkers and can detect germline (inherited) and somatic (acquired) mutations through genomic profiling of tumor tissue and/or blood. These targeted panels are useful in practice and can affect clinical decision making. The results of molecular profiling can lead to an increasing number of FDA approved treatment options and/or clinical trial opportunities with novel drugs linked to these alterations, most notably in more advanced disease. This ability to individualize treatment options has led to precision medicine, providing a more personalized approach to cancer care.